News
This newsletter brings a mixture of good news and challenges. We are a global trial, with a large contribution from Europe, but funding opportunities for such a large, collaborative, long-term effort are challenging. Currently, we need to pause recruitment at some sites for financial reasons, while we work hard to obtain new funding. Not an easy task, especially in the light of the current global landscape. More information is in this newsletter. On a more positive note, we have received approval for our first substantial modification in CTIS (including the updated CoreProtocol), we are preparing several manuscripts, the CRF is being revised to be leaner and smarter, and we are continuously optimizing the trial and our procedures. I truly hope you remain part of our family, even if we need to pause our activities for a short while, and we can continue to investigate the optimal treatment of patients with acute respiratory infections.
December is always a time for reflection. Lookingback, I am proud of what we have achieved. We have been able to streamline our operations, that are now completely aligned with Ecraid templates and procedures. We have strenghtened our collaborations through in-person meetings, and have our recruitment dashboard fully operational, as you can see in this newsletter.
As summer slowly comes to an end, we are anticipating increased trial recruitment and activities. We are preparing our first Substantial Modification in CTIS, as you will read in this newsletter. We have 7 domains open, with a special focus on influenza. Please let us know if you’re interested in participating, so we can answer important questions for patients this season!
While we cheer for our individual countries to win Euro 2024, as the European of REMAP-CAP we’ve been very successful together. Over the last 4 years, we’ve included almost 5,000 patients into the trial, adding up to over 8,200 randomizations, and our collaboration as a European trial group has strengthened.
With the spring coming, it is time for change, also for REMAP-CAP. We have entered – again – the inter-pandemic stage, with over 90% of recruitment in non-COVID-19 infections since more than a year.
At the end of 2023, we look back at our recent achievements and take a sneak preview at 2024.
With Autumn knocking on the door, hospitalizations for pneumonia are expected to increase, and we are determined to continue contributing to finding better treatments for influenza and COVID-19.
REMAP-CAP is slowly transiting from the pandemic setting to the pre-pandemic scenario with a focus on severe CAP and improving our processes based upon the lessons learned during the pandemic.
With the pandemic calming down in Europe, REMAP-CAP still delivered important conclusions for patients.
Covid-19 is (still) not gone.
ICU admissions are low, and we hope they remain low, but let’s aim to learn from those that do need hospital or ICU admission. We continue to develop domains for answering urgent clinical questions for our patients, so we can keep learning together.